These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

810 related articles for article (PubMed ID: 28028555)

  • 1. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
    Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
    Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of teriparatide adherence and persistence on fracture outcomes.
    Yu S; Burge RT; Foster SA; Gelwicks S; Meadows ES
    Osteoporos Int; 2012 Mar; 23(3):1103-13. PubMed ID: 22159748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with prior vertebral or hip fractures treated with teriparatide in the Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) observational study.
    Beall DP; Feldman RG; Gordon ML; Gruber BL; Lane JM; Valenzuela G; Yim D; Alam J; Krege JH; Krohn K
    Osteoporos Int; 2016 Mar; 27(3):1191-1198. PubMed ID: 26556737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database.
    Chan DC; Chang CH; Lim LC; Brnabic AJM; Tsauo JY; Burge R; Hsiao FY; Jin L; Gürbüz S; Yang RS
    Osteoporos Int; 2016 Sep; 27(9):2855-2865. PubMed ID: 27172935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies.
    Silverman S; Langdahl BL; Fujiwara S; Saag K; Napoli N; Soen S; Enomoto H; Melby TE; Disch DP; Marin F; Krege JH
    Calcif Tissue Int; 2019 Feb; 104(2):193-200. PubMed ID: 30343436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population.
    Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1178-1190. PubMed ID: 29083977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis.
    Bonafede MM; Shi N; Bower AG; Barron RL; Grauer A; Chandler DB
    Osteoporos Int; 2015 Mar; 26(3):1203-12. PubMed ID: 25567774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teriparatide treatment of severe osteoporosis reduces the risk of vertebral fractures compared with standard care in routine clinical practice.
    Oswald AJ; Berg J; Milne G; Ralston SH
    Calcif Tissue Int; 2014 Feb; 94(2):176-82. PubMed ID: 24026567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results.
    Silverman S; Miller P; Sebba A; Weitz M; Wan X; Alam J; Masica D; Taylor KA; Ruff VA; Krohn K
    Osteoporos Int; 2013 Aug; 24(8):2309-17. PubMed ID: 23404615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
    Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
    J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
    Levis S; Theodore G
    J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX.
    Harvey NC; Kanis JA; Odén A; Nakamura T; Shiraki M; Sugimoto T; Kuroda T; Johansson H; McCloskey EV
    Osteoporos Int; 2015 Sep; 26(9):2347-53. PubMed ID: 26092062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.
    Harvey NC; Kanis JA; Odén A; Burge RT; Mitlak BH; Johansson H; McCloskey EV
    Osteoporos Int; 2015 Nov; 26(11):2677-84. PubMed ID: 26092063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.
    Yusuf AA; Cummings SR; Watts NB; Feudjo MT; Sprafka JM; Zhou J; Guo H; Balasubramanian A; Cooper C
    Arch Osteoporos; 2018 Mar; 13(1):33. PubMed ID: 29564735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
    Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
    BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures.
    Gallagher JC; Genant HK; Crans GG; Vargas SJ; Krege JH
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1583-7. PubMed ID: 15613428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis.
    Krege JH; Wan X
    Bone; 2012 Jan; 50(1):161-4. PubMed ID: 22036910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
    McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA
    Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
    Lindsay R; Watts NB; Lange JL; Delmas PD; Silverman SL
    Osteoporos Int; 2013 Aug; 24(8):2345-52. PubMed ID: 23612793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.